← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
95%Confidence
0Views
FDASource
2026-04-18Date

Summary

Additional sterility failures for K.C. Pharmaceuticals' lubricating eye drops indicate systemic manufacturing quality issues. The involvement of multiple distributors suggests widespread market penetration of potentially contaminated products.

Actionable: Expand product recall to include all K.C. Pharmaceuticals eye drops and verify alternative suppliers for replacement stock.

AI Confidence: 95%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productUltra Lubricating Eye Drops (polyethylene 400 0.4%, propylene glycol 0.3%), Sterile, 0.5 FL OZ (15mL) bottles; a) LEADER, DISTRIBUTED BY CARDINAL HEAL

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now